Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Three blend-specific points apply
Diabetes Care 36 , 237244 (2013)
The company submitted a New Drug Application to the United States Food and Drug Administration in December 2025, based on the REDEFINE 1 and REDEFINE 2 results, with a decision anticipated late in 2026
Nanoscience Applications in Diabetes Treatment
Pfizer leverages its vast distribution network and expertise in metabolic diseases to promote GLP-1 therapies targeting obesity and type 2 diabetes
US$ 27.76
US$ 20.89
US$ 20.58
US$ 20.03
US$ 28.60
